The same event can reach both: a study opening is one line under its program in the brief, and one study’s change in the alerts.
The registry lists 1,419 studies for Glaucoma across more than 10 countries. 220 are recruiting or about to start. 986 of them are mainly about Glaucoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 5 narrower conditions too, such as Glaucoma, Open-Angle: 2,182 studies, 311 open.
ClinicalTrials.gov finds 2,256 studies for Glaucoma.How that becomes 1,419 here
This page counts the studies the registry files under Glaucoma, and those it files under no condition that list Glaucomathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count
2,256Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−24List Glaucoma as a condition, but the registry did not file them under itMost often written as “Glaucoma, Suspect” (4), “Pseudoexfoliation Glaucoma” (4), and “Primary Glaucoma” (3). The registry filed them under other conditions only, most often Ocular Hypertension (9) and Cataract (5).
−52Match it another way49 name it in the title, 2 in a keyword, and 1 by a synonym or other text the search reads.
1,419The count on this page55 of them list Glaucoma in their own words; the registry filed them under no condition.
Every program with a company-led study here in the last two years, whatever its size: 12 programs from 10 companies, 6 with this as their studies’ main aim; 2 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Alcon, Astellas Pharma and Bausch Health Companies here →
Comparator & background therapies
What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.
“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.
In phase 3
Company
Phase-3 primary completion
Meets, by arms
Gen 2 Travoprost Intracameral Implant☆ Track1 live phase-3 study: NCT07495852
Glaukos Corporation
Jun 2028 est.
vs Timolol
The 1 in phase 3 with the nearest primary completion, of 12 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.
Primary completion in the next 12 months (2)
Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.
Jan 2027 est.Drugs, Investigational· EyeD Pharma · Phase 2main aimvs TimololNCT07036510 Safety and Efficacy of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract Surgery — primary endpoint: Stage 1: Number (%) of participants experiencing adverse events · 42 enrolled
30 Jun 2027 est.Arm 1: TB0001 ophthalmic solution 0.9%· Tavo Biotherapeutics · Phase 2named, not the main aimvs TimololNCT07913074 A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure. — primary endpoint: Change from mean diurnal baseline IOP to mean diurnal IOP at Day 28 · 96 enrolled
Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.
What is being tested here
Drugs under test in Glaucoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
77studies finish main data collection within a year2 of them phase 3
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger. 13 (8%) take children under 18. 1 (1%) are for women only and 0 (0%) for men only; 44 (29%) take healthy volunteers.
Across all 1,419 studies, recruiting or not: 10% stop at 75 or younger and 6% at 65; 10% take children; <1% are for women only and 1% for men only; 26% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Glaucoma studies take
Of 44 phase 4 interventional studies under Glaucoma, half reached primary completion within 34 months of starting, counting those still running.
Start to primary completion
Every sponsor
Industry
Non-industry
Phase 1
8 mo3–23 · 18 studies
—
—
Phase 2
11 mo6–22 · 32 studies
7 mo6–11 · 23 studies
—
Phase 3
20 mo12–43 · 33 studies
20 mo12–42 · 26 studies
—
Phase 4
34 mo11–66 · 44 studies
—
34 mo12–45 · 32 studies
Interventional, no phase
30 mo12–53 · 288 studies
22 mo8–46 · 58 studies
32 mo12–55 · 230 studies
Observational
31 mo12–208 · 134 studies
—
47 mo12–208 · 110 studies
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 18, 2026.